Skip to content
Journal ArticleNature medicine·Graded and published ·Last edited

Tirzepatide Plus Weight Training: Strength Rose Instead of Falling

Graded Moderate — a trial that assigned 120 adults to two groups at random for 40 weeks; it is too small and short to judge long-term effects.

Design
Randomized controlled trial
Participants
120
Duration
9 months
Funding
Western Australian State Government Research Excellence Award; Australian…
Key Insight

People on tirzepatide who did weight training lost less lean mass and got stronger rather than weaker.


Weight-loss injections melt away many kilos. But along with fat, people also lose lean mass, which is mostly muscle. In a trial from Australia, weight training slowed that loss. And while strength fell without training, it went up with it.

The trial gave 120 adults with overweight or obesity tirzepatide for 40 weeks. The drug mimics gut hormones and is injected once a week. Half were chosen at random to add weight training three times a week. The others kept to their usual routine. Both groups lost a little over 22 kilos. Without training they lost 4.7 kilos of lean mass, with training 3.6 kilos.

On the bench press, the training group lifted almost 4.7 kilos more by the end, while the others lifted about 4 kilos less. The pattern was similar for pulling and leg exercises. Fat loss showed no clear difference between the groups. Attendance at training was 91 percent. Whether the smaller loss of lean mass matters later in daily life is not known, since the trial lasted 40 weeks.

Conflict of Interest Disclosure: Several authors received speaker or advisory fees from Eli Lilly, Novo Nordisk and other companies.

Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.